What Makes CJC-1295 DAC Different from Regular CJC-1295?

[Anabolix]

What Makes CJC-1295 DAC Different from Regular CJC-1295?​

CJC-1295 is one of the most talked-about peptides in growth hormone research. It belongs to a class of compounds known as Growth Hormone Releasing Hormone (GHRH) analogs, meaning it stimulates the pituitary gland to release more growth hormone (GH), which in turn can increase levels of IGF-1 (Insulin-Like Growth Factor-1).

However, one of the most common points of confusion is that CJC-1295 actually exists in two different forms:

• CJC-1295 with DAC
• CJC-1295 without DAC (often called Mod GRF 1-29)

While both share the same core peptide structure, the presence of DAC (Drug Affinity Complex) dramatically changes how the peptide behaves in the body. Understanding this difference is important because it affects half-life, dosing frequency, hormone release patterns, and research applications.

Understanding CJC-1295: The Basics

CJC-1295 is a modified version of natural Growth Hormone Releasing Hormone. GHRH is produced in the hypothalamus and signals the pituitary gland to release growth hormone.

Scientists modified this peptide with several amino-acid substitutions to make it more stable and resistant to breakdown in the body. These changes help:

• Improve receptor binding
• Increase peptide stability
• Extend the functional activity of GHRH signaling

The goal of CJC-1295 is to promote a stronger and longer-lasting GH release compared to natural GHRH.

Where things become interesting is when the DAC modification is added.

What Is DAC (Drug Affinity Complex)?

DAC stands for Drug Affinity Complex. It is a chemical structure attached to the peptide that allows it to bind to a circulating blood protein called serum albumin.

Albumin acts like a carrier protein in the bloodstream. When CJC-1295 DAC binds to albumin, it becomes protected from rapid breakdown by enzymes and kidney filtration.

This attachment dramatically increases how long the peptide remains active in the body.

In simple terms:

DAC = Extended circulation time

And this is what separates the two versions.

​

Half-Life: The Biggest Difference

The most important distinction between the two peptides is their half-life.

CJC-1295 with DAC

• Half-life: approximately 6–8 days
• Growth hormone release: prolonged and sustained
• Dosing frequency: typically once or twice per week

Because the peptide remains in circulation for several days, it continuously stimulates GH release during that time.

CJC-1295 without DAC (Mod GRF 1-29)

• Half-life: about 30 minutes to 2 hours
• Growth hormone release: short pulses
• Dosing frequency: often multiple times per day

This shorter half-life allows researchers to create controlled GH pulses similar to the body's natural secretion patterns.

Growth Hormone Release Patterns

Another key difference is how GH levels are stimulated.

CJC-1295 DAC: Sustained GH Elevation

With DAC attached, the peptide stays active for days, leading to a longer period of GH stimulation.

Advantages include:

• Long-lasting GH activity
• Very infrequent injections
• Stable IGF-1 elevation

However, the GH release is more constant rather than pulsatile.

CJC-1295 without DAC: Pulsatile GH Release

Without DAC, the peptide causes a short burst of GH followed by a return to baseline.

Advantages include:

• Mimics natural GH pulses
• More control over timing
• Easier to combine with other peptides in protocols

The trade-off is that the peptide must be administered more frequently due to its short half-life.

Structural Differences

Both versions share the same basic peptide backbone consisting of a modified 29-amino-acid GHRH analog.

The DAC version includes an additional molecular component that allows it to bind to albumin in the bloodstream. This attachment slows elimination and significantly extends the peptide’s functional lifespan.

Without DAC, the peptide is cleared much faster by enzymatic degradation and renal filtration.

Dosing Convenience Comparison

Here is a simplified comparison:

CJC-1295 DAC

• Long half-life (~1 week)
• Sustained GH release
• 1–2 injections per week

CJC-1295 No DAC (Mod GRF 1-29)

• Short half-life (~30 minutes)
• Pulsatile GH release
• Multiple injections per day

This difference in convenience and hormone release pattern is why the two peptides are often used for different research approaches.

Which One Is More “Natural”?

In the human body, growth hormone is normally released in pulses, especially during deep sleep and after intense physical activity.

Because of this, some researchers consider the non-DAC version closer to natural physiology, since it produces short GH spikes followed by a return to baseline.

CJC-1295 DAC, on the other hand, creates a longer and more sustained elevation in GH levels.

Both approaches have their own advantages depending on the goal of the research protocol.

Final Thoughts

Although both peptides originate from the same GHRH analog, the addition of the Drug Affinity Complex dramatically alters how CJC-1295 behaves in the body.

CJC-1295 DAC

• Very long half-life
• Sustained GH stimulation
• Minimal dosing frequency

CJC-1295 without DAC (Mod GRF 1-29)

• Short half-life
• Pulsatile GH release
• Requires frequent dosing

The key difference ultimately comes down to duration of action and hormone release patterns. Understanding this distinction helps researchers choose the version that best fits their intended application.